{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:18:10Z","timestamp":1772165890103,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,2]],"date-time":"2021-10-02T00:00:00Z","timestamp":1633132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,2]],"date-time":"2021-10-02T00:00:00Z","timestamp":1633132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Systemic manifestations and comorbidities are characteristics of chronic obstructive pulmonary disease (COPD) and are probably due to systemic inflammation. The histone methyltransferase SUV39H1 controls the Th1\/Th2 balance. We previously reported that reduced SUV39H1 expression contributed to abnormal inflammation in COPD. Here, we aimed to determine whether impaired SUV39H1 expression in COPD patients associated with neutrophilic\/eosinophilic inflammation responses and comorbidities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 213 COPD patients and 13 healthy controls were recruited from the Shuang Ho Hospital, Taipei Medical University. SUV39H1 levels in peripheral blood mononuclear cells (PBMCs) from 13 healthy and 30 COPD participants were measured by immunoblotting. We classified the patients into two groups based on low (fold change, FC\u2009&lt;\u20090.5) and high SUV39H1 expression (FC\u2009\u2265\u20090.5) compared to normal controls. Clinical outcomes including neutrophil or eosinophil counts associated with SUV39H1-related inflammation were evaluated by Chi square analyses or Mann\u2013Whitney U test. The correlations between the percentage of neutrophils and number of COPD comorbidities or Charlson Comorbidity Index (CCI) scores were performed by Spearman\u2019s rank analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Low SUV39H1 expression group had high neutrophil counts relative to high SUV39H1expression group. In the COPD cohort, the high comorbidity group (\u2265\u20092 comorbidities) had higher counts of whole white blood cell (WBC) and neutrophil, and lower proportion of eosinophil and eosinophil\/neutrophil, as compared with low comorbidity group (0 and 1 comorbidities). The quantity of neutrophils was associated with COPD comorbidities (Spearman's\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.388,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), but not with CCI scores. We also found that the high comorbidity group had more exacerbations per year compared with low comorbidity group (1.5 vs. 0.9 average exacerbations,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005). However, there were no significant differences between groups with these non-frequent (0\u20131 exacerbation) and frequent exacerbations per year (&gt;\u20091 exacerbation) in numbers of WBC and proportion of neutrophils, eosinophils or eosinophil\/neutrophil. Finally, patients with high comorbidities had lower SUV39H1 levels in their PBMCs than did those with low comorbidities.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Blood neutrophil counts are associated with comorbidities in COPD patients. Impaired SUV39H1 expression in PBMCs from COPD patients are correlated with neutrophilic inflammation and comorbidities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12890-021-01628-x","type":"journal-article","created":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T20:54:32Z","timestamp":1633121672000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Suppressor of variegation 3\u20139 homologue 1 impairment and neutrophil-skewed systemic inflammation are associated with comorbidities in COPD"],"prefix":"10.1186","volume":"21","author":[{"given":"Tzu-Tao","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng-Ming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuan-Yuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Hua","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Chuan","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsiao-Chi","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Po-Hao","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Te","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Li","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erick Wan-Chun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-Kai","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4705-5802","authenticated-orcid":false,"given":"Kang-Yun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,2]]},"reference":[{"issue":"5","key":"1628_CR1","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1183\/09031936.00128008","volume":"33","author":"PJ Barnes","year":"2009","unstructured":"Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33(5):1165\u201385.","journal-title":"Eur Respir J"},{"key":"1628_CR2","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.2147\/COPD.S120637","volume":"11","author":"S Deniz","year":"2016","unstructured":"Deniz S, Sengul A, Aydemir Y, Celdir Emre J, Ozhan MH. Clinical factors and comorbidities affecting the cost of hospital-treated COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:3023\u201330.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"8","key":"1628_CR3","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1093\/qjmed\/hcv212","volume":"109","author":"GP Currie","year":"2016","unstructured":"Currie GP, Lipworth BJ. Inhaled treatment for chronic obstructive pulmonary disease: what\u2019s new and how does it fit? QJM. 2016;109(8):505\u201312.","journal-title":"QJM"},{"key":"1628_CR4","first-page":"CD012930","volume":"3","author":"U Maqsood","year":"2019","unstructured":"Maqsood U, Ho TN, Palmer K, Eccles FJ, Munavvar M, Wang R, et al. Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2019;3:CD012930.","journal-title":"Cochrane Database Syst Rev"},{"issue":"16","key":"1628_CR5","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.2174\/1389450119666180212120012","volume":"19","author":"K Kostikas","year":"2018","unstructured":"Kostikas K, Brindicci C, Patalano F. Blood eosinophils as biomarkers to drive treatment choices in asthma and COPD. Curr Drug Targets. 2018;19(16):1882\u201396.","journal-title":"Curr Drug Targets"},{"issue":"1","key":"1628_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12931-019-1268-7","volume":"21","author":"TH Harries","year":"2020","unstructured":"Harries TH, Rowland V, Corrigan CJ, Marshall IJ, McDonnell L, Prasad V, et al. Blood eosinophil count, a marker of inhaled corticosteroid effectiveness in preventing COPD exacerbations in post-hoc RCT and observational studies: systematic review and meta-analysis. Respir Res. 2020;21(1):3.","journal-title":"Respir Res"},{"key":"1628_CR7","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.2147\/COPD.S155306","volume":"14","author":"DK Narendra","year":"2019","unstructured":"Narendra DK, Hanania NA. Targeting IL-5 in COPD. Int J Chron Obstruct Pulmon Dis. 2019;14:1045\u201351.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"11","key":"1628_CR8","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1164\/rccm.201602-0353OC","volume":"194","author":"M Suzuki","year":"2016","unstructured":"Suzuki M, Makita H, Konno S, Shimizu K, Kimura H, Kimura H, et al. Asthma-like features and clinical course of chronic obstructive pulmonary disease. An analysis from the Hokkaido COPD cohort study. Am J Respir Crit Care Med. 2016;194(11):1358\u201365.","journal-title":"Am J Respir Crit Care Med"},{"issue":"7406","key":"1628_CR9","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature11173","volume":"487","author":"RS Allan","year":"2012","unstructured":"Allan RS, Zueva E, Cammas F, Schreiber HA, Masson V, Belz GT, et al. An epigenetic silencing pathway controlling T helper 2 cell lineage commitment. Nature. 2012;487(7406):249\u201353.","journal-title":"Nature"},{"key":"1628_CR10","doi-asserted-by":"publisher","first-page":"46667","DOI":"10.1038\/srep46667","volume":"7","author":"TT Chen","year":"2017","unstructured":"Chen TT, Wu SM, Ho SC, Chuang HC, Liu CY, Chan YF, et al. SUV39H1 reduction is implicated in abnormal inflammation in COPD. Sci Rep. 2017;7:46667.","journal-title":"Sci Rep"},{"issue":"4","key":"1628_CR11","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1164\/rccm.201204-0596PP","volume":"187","author":"J Vestbo","year":"2013","unstructured":"Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347\u201365.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"1628_CR12","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383.","journal-title":"J Chronic Dis"},{"issue":"4","key":"1628_CR13","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1183\/09031936.00146811","volume":"40","author":"KY Lee","year":"2012","unstructured":"Lee KY, Ho SC, Chan YF, Wang CH, Huang CD, Liu WT, et al. Reduced nuclear factor-kappaB repressing factor: a link toward systemic inflammation in COPD. Eur Respir J. 2012;40(4):863\u201373.","journal-title":"Eur Respir J"},{"key":"1628_CR14","doi-asserted-by":"publisher","first-page":"14941","DOI":"10.1038\/ncomms14941","volume":"8","author":"G Yang","year":"2017","unstructured":"Yang G, Weng X, Zhao Y, Zhang X, Hu Y, Dai X, et al. The histone H3K9 methyltransferase SUV39H links SIRT1 repression to myocardial infarction. Nat Commun. 2017;8:14941.","journal-title":"Nat Commun"},{"issue":"3","key":"1628_CR15","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2165\/00151829-200403030-00003","volume":"3","author":"S Kim","year":"2004","unstructured":"Kim S, Nadel JA. Role of neutrophils in mucus hypersecretion in COPD and implications for therapy. Treat Respir Med. 2004;3(3):147\u201359.","journal-title":"Treat Respir Med"},{"issue":"3","key":"1628_CR16","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1136\/thx.51.3.267","volume":"51","author":"D Stanescu","year":"1996","unstructured":"Stanescu D, Sanna A, Veriter C, Kostianev S, Calcagni PG, Fabbri LM, et al. Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils. Thorax. 1996;51(3):267\u201371.","journal-title":"Thorax"},{"issue":"4","key":"1628_CR17","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1378\/chest.128.4.1995","volume":"128","author":"GC Donaldson","year":"2005","unstructured":"Donaldson GC, Seemungal TA, Patel IS, Bhowmik A, Wilkinson TM, Hurst JR, et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest. 2005;128(4):1995\u20132004.","journal-title":"Chest"},{"key":"1628_CR18","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/1465-9921-7-136","volume":"7","author":"DG Parr","year":"2006","unstructured":"Parr DG, White AJ, Bayley DL, Guest PJ, Stockley RA. Inflammation in sputum relates to progression of disease in subjects with COPD: a prospective descriptive study. Respir Res. 2006;7:136.","journal-title":"Respir Res"},{"issue":"7","key":"1628_CR19","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1136\/thoraxjnl-2013-204778","volume":"69","author":"R Faner","year":"2014","unstructured":"Faner R, Tal-Singer R, Riley JH, Celli B, Vestbo J, MacNee W, et al. Lessons from ECLIPSE: a review of COPD biomarkers. Thorax. 2014;69(7):666\u201372.","journal-title":"Thorax"},{"issue":"6","key":"1628_CR20","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/crj.13025","volume":"13","author":"JM Figueira-Goncalves","year":"2019","unstructured":"Figueira-Goncalves JM, Golpe R, Garcia-Bello MA, Garcia-Talavera I, Castro-Anon O. Comparison of the prognostic capability of two comorbidity indices in patients with chronic obstructive pulmonary disease, in real-life clinical practice. Clin Respir J. 2019;13(6):404\u20137.","journal-title":"Clin Respir J"},{"issue":"9","key":"1628_CR21","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1164\/rccm.201008-1285OC","volume":"183","author":"E Sapey","year":"2011","unstructured":"Sapey E, Stockley JA, Greenwood H, Ahmad A, Bayley D, Lord JM, et al. Behavioral and structural differences in migrating peripheral neutrophils from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011;183(9):1176\u201386.","journal-title":"Am J Respir Crit Care Med"},{"key":"1628_CR22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1471-2466-9-25","volume":"9","author":"N Louhelainen","year":"2009","unstructured":"Louhelainen N, Rytila P, Haahtela T, Kinnula VL, Djukanovic R. Persistence of oxidant and protease burden in the airways after smoking cessation. BMC Pulm Med. 2009;9:25.","journal-title":"BMC Pulm Med"},{"key":"1628_CR23","doi-asserted-by":"crossref","unstructured":"Kim VL, Coombs NA, Staples KJ, Ostridge KK, Williams NP, Wootton SA, et al. Impact and associations of eosinophilic inflammation in COPD: analysis of the AERIS cohort. Eur Respir J. 2017;50(4).","DOI":"10.1183\/13993003.00853-2017"},{"issue":"1","key":"1628_CR24","doi-asserted-by":"publisher","first-page":"13451","DOI":"10.1038\/s41598-017-13745-x","volume":"7","author":"J Ho","year":"2017","unstructured":"Ho J, He W, Chan MTV, Tse G, Liu T, Wong SH, et al. Eosinophilia and clinical outcome of chronic obstructive pulmonary disease: a meta-analysis. Sci Rep. 2017;7(1):13451.","journal-title":"Sci Rep"},{"issue":"1","key":"1628_CR25","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s12931-019-1198-4","volume":"20","author":"M Hosseini","year":"2019","unstructured":"Hosseini M, Almasi-Hashiani A, Sepidarkish M, Maroufizadeh S. Global prevalence of asthma-COPD overlap (ACO) in the general population: a systematic review and meta-analysis. Respir Res. 2019;20(1):229.","journal-title":"Respir Res"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-021-01628-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-021-01628-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-021-01628-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T20:56:14Z","timestamp":1633121774000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-021-01628-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,2]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1628"],"URL":"https:\/\/doi.org\/10.1186\/s12890-021-01628-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-45674\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-45674\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-45674\/v3","asserted-by":"object"}]},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,2]]},"assertion":[{"value":"21 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by were approved by an independent ethics committee. (Taipei Medical University-Joint Institutional Review Board, TMU-JIRB N201502024 and N201802023). For a retrospective observational study, all data were anonymously used and this study does not contain protected health information, the ethics committee approved a waiver of the requirement for informed consent. Individual patients consent was not obtained since all data used in this study were acquired retrospectively from the clinical or laboratory information system without any additional sampling or laboratory analysis. Patients could choose to opt out at any time and have their data removed from the registry. In an observational study, all blood samples from participants provided written informed consent prior to any study-related procedure. All experiments were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The dataset used and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"The authors declare that they have no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"276"}}